Chun-Jie Li1, Guanwei Zhang2, Yingyi Zhang3, Hongliang Cong3, Bo-Li Zhang2. 1. Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine Tianjin 300193, China ; Tianjin Chest Hospital Tianjin, China. 2. Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine Tianjin 300193, China. 3. Tianjin Chest Hospital Tianjin, China.
Abstract
AIM: To assess the efficacy and safety of combining Xinkeshu tablet treatment with routine Western medicine treatment for patients with coronary heart disease (CHD) and mood disorders after PCI postoperative period. METHOD: 100 patients were randomly divided into treatment group of 50 cases, and control group of 50 cases. The control group was given routine Western medical treatment, whereas the treatment group was given routine Western medical treatment in combination with Xinkeshu tablets. Eight weeks after treatment, the patients underwent SF-36 life quality evaluation, self-rating depression scale (SDS) evaluation, and self-rating anxiety scale (SAS) evaluation. RESULT: After the eight-week treatment, the SF-36 life quality scores, SAS scores, SDS score, as well as the reduction in heart creatinine levels of the two groups were compared. The results show statistical significance (P<0.05). CONCLUSION: Xinkeshu can effectively address the PCI postoperative mood disorders in patients with coronary heart disease and improve the quality of life.
RCT Entities:
AIM: To assess the efficacy and safety of combining Xinkeshu tablet treatment with routine Western medicine treatment for patients with coronary heart disease (CHD) and mood disorders after PCI postoperative period. METHOD: 100 patients were randomly divided into treatment group of 50 cases, and control group of 50 cases. The control group was given routine Western medical treatment, whereas the treatment group was given routine Western medical treatment in combination with Xinkeshu tablets. Eight weeks after treatment, the patients underwent SF-36 life quality evaluation, self-rating depression scale (SDS) evaluation, and self-rating anxiety scale (SAS) evaluation. RESULT: After the eight-week treatment, the SF-36 life quality scores, SAS scores, SDS score, as well as the reduction in heart creatinine levels of the two groups were compared. The results show statistical significance (P<0.05). CONCLUSION: Xinkeshu can effectively address the PCI postoperative mood disorders in patients with coronary heart disease and improve the quality of life.